nach oben

Current Diabetes Reports

Erschienen in:

12.02.2022 | Pediatric Type 2 and Monogenic Diabetes (O Pinhas-Hamiel, Section Editor)

Contraception for Adolescents and Young Women with Type 2 Diabetes–Specific Considerations

verfasst von: Paulina M. Merino, Ethel Codner

Erschienen in: Current Diabetes Reports | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This article reviews how to address contraception in young women with type 2 diabetes (T2D). The presence of obesity and comorbidities associated with insulin resistance increases the risk of thromboembolic disease and adverse cardiovascular outcomes.

Recent Findings

Recent studies have shown that adolescents with T2D are at high risk of unintended pregnancy with poor outcomes for the mother and offspring. Adolescents with T2D without severe obesity, micro- or macrovascular disease, or other cardiovascular risk factors can use any contraceptive method. However, only nonhormonal or progestin-only methods may be used when morbid obesity, severe hypertension, micro- or macrovascular disease, or multiple cardiovascular risk factors are present.

Summary

The medical team must provide preconceptional counseling and contraception to reduce adolescent pregnancies in young women with T2D. Progestin-only or nonhormonal long-acting reversible contraception (LARC) should be recommended for women with T2D with compliance issues or adverse cardiovascular risk profiles.

Koren D, Levitsky LL. Type 2 diabetes mellitus in childhood and adolescence. Pediatr Rev. 2021;42(4):167–79. https://doi.org/10.1542/pir.2019-0236.CrossRefPubMed

Kohn JR, Rajan SS, Kushner JA, Fox KA. Outcomes, care utilization, and expenditures in adolescent pregnancy complicated by diabetes. Pediatr Diabetes. 2019;20(6):769–77. https://doi.org/10.1111/pedi.12871.CrossRefPubMed

Klingensmith GJ, Pyle L, Nadeau KJ, Barbour LA, Goland RS, Willi SM, et al. Pregnancy outcomes in youth with type 2 diabetes: the TODAY study experience. Diabetes Care. 2016;39(1):122–9. https://doi.org/10.2337/dc15-1206.CrossRefPubMed

Barbour LA. Changing perspectives in pre-existing diabetes and obesity in pregnancy: maternal and infant short- and long-term outcomes. Curr Opin Endocrinol Diabetes Obes. 2014;21(4):257–63. https://doi.org/10.1097/MED.0000000000000079.CrossRefPubMed

Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, de Mouzon SH, et al. Perinatal risk factors for childhood obesity and metabolic dysregulation. Am J Clin Nutr. 2009;90(5):1303–13. https://doi.org/10.3945/ajcn.2008.27416.CrossRefPubMedPubMedCentral

Whitaker RC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics. 2004;114(1):e29-36. https://doi.org/10.1542/peds.114.1.e29.CrossRefPubMed

Villarroel C, Salinas A, Lopez P, Kohen P, Rencoret G, Devoto L, et al. Pregestational type 2 diabetes and gestational diabetes exhibit different sexual steroid profiles during pregnancy. Gynecol Endocrinol. 2017;33(3):212–7. https://doi.org/10.1080/09513590.2016.1248933.CrossRefPubMed

Salinas A, Merino PM, Giraudo F, Codner E. Long-acting contraception in adolescents and young women with type 1 and type 2 diabetes. Pediatr Diabetes. 2020;21(7):1074–82. https://doi.org/10.1111/pedi.13069.CrossRefPubMed

Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007;33(2):223–33. https://doi.org/10.1016/j.ejvs.2006.10.006.CrossRefPubMed

10.

Carmine L. Contraception for adolescents with medically complex conditions. Curr Probl Pediatr Adolesc Health Care. 2018;48(12):345–57. https://doi.org/10.1016/j.cppeds.2018.11.004.CrossRefPubMed

11.

de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813. https://doi.org/10.1002/14651858.CD010813.pub2.

12.

Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis. Expert Rev Clin Pharmacol. 2017;10(10):1129–44. https://doi.org/10.1080/17512433.2017.1356718.CrossRefPubMed

13.

Sandset PM. Mechanisms of hormonal therapy related thrombosis. Thromb Res. 2013;131(Suppl 1):S4-7. https://doi.org/10.1016/S0049-3848(13)70009-4.CrossRefPubMed

14.

Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. Thromb Res. 2020;192:40–51. https://doi.org/10.1016/j.thromres.2020.05.008.CrossRefPubMedPubMedCentral

15.

Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol. 2012;24(4):235–40. https://doi.org/10.1097/GCO.0b013e328355871d.CrossRefPubMed

16.

Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95(2):130–9. https://doi.org/10.1016/j.contraception.2016.10.005.CrossRefPubMed

17.

Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril. 2016;106(6):1289–94. https://doi.org/10.1016/j.fertnstert.2016.08.039.CrossRefPubMed

18.

Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Today Study Group, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385(5):416–26. https://doi.org/10.1056/NEJMoa2100165.CrossRefPubMed

19.

García Raso A, Ene G, Miranda C, Vidal R, Mata R, Llamas Sillero MP. Association between venous thrombosis and dyslipidemia. Med Clin (Barc). 2014;143(1):1–5. https://doi.org/10.1016/j.medcli.2013.07.024.CrossRef

20.

Poredos P, Jezovnik MK. Dyslipidemia, statins, and venous thromboembolism. Semin Thromb Hemost. 2011;37(8):897–902. https://doi.org/10.1055/s-0031-1297368.CrossRefPubMed

21.

Tryggestad JB, Willi SM. Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial. J Diabetes Complications. 2015;29(2):307–12. https://doi.org/10.1016/j.jdiacomp.2014.10.009.CrossRefPubMed

22.

Nan B, Yang H, Yan S, Lin PH, Lumsden AB, Yao Q, et al. C-reactive protein decreases expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Surgery. 2005;138(2):212–22. https://doi.org/10.1016/j.surg.2005.06.003.CrossRefPubMed

23.

Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart Views. 2017;18(3):109–14. https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_106_17.CrossRefPubMedPubMedCentral

24.

Lindley KJ, Bairey Merz CN, Davis MB, Madden T, Park K, Bello NA, et al. Contraception and reproductive planning for women with cardiovascular disease: JACC Focus Seminar 5/5. J Am Coll Cardiol. 2021;77(14):1823–34. https://doi.org/10.1016/j.jacc.2021.02.025.CrossRefPubMedPubMedCentral

25.

Park K, Bairey Merz CN, Bello NA, Davis M, Duvernoy C, Elgendy IY, et al. Management of women with acquired cardiovascular disease from pre-conception through pregnancy and postpartum: JACC Focus Seminar 3/5. J Am Coll Cardiol. 2021;77(14):1799–812. https://doi.org/10.1016/j.jacc.2021.01.057.CrossRefPubMedPubMedCentral

26.

Wei Y, Lai B, Liu H, Li Y, Zhen W, Fu L. Effect of cigarette smoke extract and nicotine on the expression of thrombomodulin and endothelial protein C receptor in cultured human umbilical vein endothelial cells. Mol Med Rep. 2018;17(1):1724–30. https://doi.org/10.3892/mmr.2017.8070.CrossRefPubMed

27.

Kaneshiro B, Edelman A. Contraceptive considerations in overweight teens. Curr Opin Obstet Gynecol. 2011;23(5):344–9. https://doi.org/10.1097/GCO.0b013e328348ec82.CrossRefPubMed

28.

Dragoman MV, Simmons KB, Paulen ME, Curtis KM. Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review. Contraception. 2017;95(2):117–29. https://doi.org/10.1016/j.contraception.2016.10.010.CrossRefPubMed

29.

Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77(2 Suppl 2):S13–8. https://doi.org/10.1016/s0015-0282(01)03275-7.CrossRefPubMed

30.

Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 2011;117(1):33–40. https://doi.org/10.1097/AOG.0b013e31820095a2.CrossRefPubMed

31.

Luo D, Westhoff CL, Edelman AB, Natavio M, Stanczyk FZ, Jusko WJ. Altered pharmacokinetics of combined oral contraceptives in obesity - multistudy assessment. Contraception. 2019;99(4):256–63. https://doi.org/10.1016/j.contraception.2018.12.009.CrossRefPubMedPubMedCentral

32.

Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68(2):89–96. https://doi.org/10.1016/s0010-7824(03)00141-0.CrossRefPubMed

33.

Natavio M, Stanczyk FZ, Molins EAG, Nelson A, Jusko WJ. Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. Contraception. 2019;99(5):306–11. https://doi.org/10.1016/j.contraception.2019.01.003.CrossRefPubMedPubMedCentral

34.

Jatlaoui TC, Curtis KM. Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review. Contraception. 2016;94(6):605–11. https://doi.org/10.1016/j.contraception.2016.05.002.CrossRefPubMedPubMedCentral

35.

Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR, et al. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception. 2017;95(5):464–9. https://doi.org/10.1016/j.contraception.2017.01.004.CrossRefPubMed

36.

Bellows BK, Tak CR, Sanders JN, Turok DK, Schwarz EB. Cost-effectiveness of emergency contraception options over 1 year. Am J Obstet Gynecol. 2018;218(5):508.e1-e9. https://doi.org/10.1016/j.ajog.2018.01.025.CrossRef

37.

Rocca ML, Palumbo AR, Visconti F, Di Carlo C. Safety and benefits of contraceptives implants: a systematic review. Pharmaceuticals. 2021;14(6):548–76. https://doi.org/10.3390/ph14060548.CrossRefPubMedPubMedCentral

38.

FSRH Guideline (April 2019) Overweight, obesity and contraception. BMJ Sex Reprod Health. 2019;45:1–69.

39.

Thong EP, Codner E, Laven JSE, Teede H. Diabetes: a metabolic and reproductive disorder in women. Lancet Diabetes Endocrinol. 2020;8(2):134–49. https://doi.org/10.1016/S2213-8587(19)30345-6.CrossRefPubMed

40.

Codner E, Merino PM, Tena-Sempere M. Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update. 2012;18(5):568–85. https://doi.org/10.1093/humupd/dms024.CrossRefPubMed

41.

Barbieri RL, Makris A, Ryan KJ. Effects of insulin on steroidogenesis in cultured porcine ovarian theca. Fertil Steril. 1983;40(2):237–41.CrossRefPubMed

42.

Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986;62(5):904–10. https://doi.org/10.1210/jcem-62-5-904.CrossRefPubMed

43.

Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 1988;123(2):733–9. https://doi.org/10.1210/endo-123-2-733.CrossRefPubMed

44.

Nickles MC, Alderman E. Noncontraceptive use of contraceptive agents. Pediatr Rev. 2014;35(6):229–42. https://doi.org/10.1542/pir.35-6-229 (quiz 42).CrossRefPubMed

45.

WHO. Medical eligibility criteria for contraceptive use. 5th edn. Geneva: WHO; 2015. https://www.who.int/publications/i/item/9789241549158.

46.

Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–103. https://doi.org/10.15585/mmwr.rr6503a1.CrossRefPubMed

47.

Shaw KA, Edelman AB. Obesity and oral contraceptives: a clinician’s guide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):55–65. https://doi.org/10.1016/j.beem.2012.09.001.CrossRefPubMed

48.

Singhal S, Kumar S. Current perspectives on management of type 2 diabetes in youth. Children. 2021;8(1):37–52. https://doi.org/10.3390/children8010037.CrossRefPubMedPubMedCentral

49.

Visser J, Snel M, Van Vliet HAAM. Hormonal versus non‐hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database Syst Rev. 2013;(3):CD003990. https://doi.org/10.1002/14651858.CD003990.pub4.

50.

Robinson A, Nwolise C, Shawe J. Contraception for women with diabetes: challenges and solutions. Open Access J Contracept. 2016;7:11–8. https://doi.org/10.2147/OAJC.S56348.CrossRefPubMedPubMedCentral

51.

Codner E, Soto N, Merino PM. Contraception, and pregnancy in adolescents with type 1 diabetes: a review. Pediatr Diabetes. 2012;13(1):108–23. https://doi.org/10.1111/j.1399-5448.2011.00825.x.CrossRefPubMed

52.

Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;(4):CD006133. https://doi.org/10.1002/14651858.CD006133.pub5.

53.

Bastianelli C, Farris M, Rosato E, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev Clin Pharmacol. 2017;10(3):315–26. https://doi.org/10.1080/17512433.2017.1271708.CrossRefPubMed

54.

Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord. 2011;12(2):63–75. https://doi.org/10.1007/s11154-011-9182-4.CrossRefPubMed

55.

Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013;88(4):503–8. https://doi.org/10.1016/j.contraception.2013.03.004.CrossRefPubMedPubMedCentral

56.

Bahamondes L, Brache V, Ali M, Habib N, WHO study group on contraceptive implants for women. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement. Contraception. 2018;98(3):181–7. https://doi.org/10.1016/j.contraception.2018.05.009.CrossRefPubMed

57.

Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res. 2000;26(1):17–26. https://doi.org/10.1111/j.1447-0756.2000.tb01195.x.CrossRefPubMed

58.

Vicente L, Mendonça D, Dingle M, Duarte R, Boavida JM. Etonogestrel implant in women with diabetes mellitus. Eur J Contracept Reprod Health Care. 2008;13(4):387–95. https://doi.org/10.1080/13625180802382604.CrossRefPubMed

59.

Lang B, Josephy T, Micks E, McCoy E, Prager S. Use of the Levonorgestrel intrauterine device in women with type 2 diabetes. Clin Diabetes. 2018;36(3):251–6. https://doi.org/10.2337/cd17-0028.CrossRefPubMedPubMedCentral

60.

Goldstuck ND, Steyn PS. The intrauterine device in women with diabetes mellitus type I and II: a systematic review. ISRN Obstet Gynecol. 2013;2013:814062. https://doi.org/10.1155/2013/814062.CrossRefPubMedPubMedCentral

Titel: Contraception for Adolescents and Young Women with Type 2 Diabetes–Specific Considerations
verfasst von: Paulina M. Merino
Ethel Codner
Publikationsdatum: 12.02.2022
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 2/2022
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-022-01448-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen